A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.
Cambridge Bioscience will be NanoInk's exclusive distributor in the UK and Ireland, NanoInk said this week.
NanoInk has tapped two distributors to sell its nanofabrication platforms in the Asia Pacific region.
Avantra Biosciences' Rapid Assay Prototyping Service, NanoInk's NanoArray Assay System
Roughly 40 percent of the funding will go toward NanoInk's BioDiscovery division, where it will be used to build out the company's sales and marketing organization and fund development of new products based on its protein nanoarray platform.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.
A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.
Vox writes that lab mishaps involving pathogens are quite common.
In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.